Emerging Trends in Overactive Bladder Treatment Market With Industry Players like ALLERGAN, APOTEX, ASTELLAS PHARMA, AUROBINDO PHARMA LIMITED, COGENTIX MEDICAL, ENDO INTERNATIONAL, INTAS PHARMACEUTICALS

The global overactive bladder treatment market is expected to register a CAGR of about 2.9% over the forecast period, 2018-2023. The overactive bladder treatments includes various therapies like, anticholinergics, mirabegron, etc., that are used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence.

Get Sample Copy of this report @ https://marketprognosis.com/sample-request/17149

Aging Population and Rising Incidence of Diseases Characterized By OAB
In 2017, there were approximately 950 million people who were 60 years old or above, comprising 13% of the global population, and is growing by about 3% every year. Incontinence generally increases with aging. As per a global population-based survey, the estimated prevalence of overactive bladder (OAB) in Europe and Canada was found to be 12.8% in women and 10.8% in men. OAB has a major negative impact on quality of life and health of the aged population. With the increasing burden of OAB, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as the development of innovative intravesical therapies and aggressive marketing by pharmaceuticals companies, are also expected to expand the market.

Major Players:
ALLERGAN PLC., APOTEX INC., ASTELLAS PHARMA INC., AUROBINDO PHARMA LIMITED, COGENTIX MEDICAL INC., ENDO INTERNATIONAL PLC, HISAMITSU PHARMACEUTICAL CO. INC., INTAS PHARMACEUTICALS LTD, JOHNSON & JOHNSON, MACLEODS PHARMACEUTICALS LTD, MEDTRONIC PLC, MYLAN NV, PFIZER INC., SANOFI, AND TEVA PHARMACEUTICAL INDUSTRIES LIMITED, amongst others.

Enquiry Before Buying @ https://marketprognosis.com/enquiry/17149

Undesired Systemic Effects of the Current OAB Treatments
Anticholinergic have been linked to the burden to dementia or Alzheimer’s disease in a few recent studies. In a recent publication by SL Gray, 3434 participants were studied and a 10-year cumulative dose response relationship was found to exist between the usage of anticholinergic drugs and the risk of developing dementia. Anticholinergic has also been linked with increased mortality and cardiovascular diseases. These factors may deter healthcare providers from using these treatment options. Also the increasing awareness about these side effects among users will lead to the slowdown of the growth of this market.

North America to Dominate the Market
North America has dominated the overactive bladder treatment market, which can be primarily attributed to its well-established healthcare industry which has favorable reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players. Asia-Pacific region is expected to witness the highest CAGR during the forecast period, due to rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness of overactive bladder.

Browse Report @ https://marketprognosis.com/report/global-overactive-bladder-treatment-market---segmented-by-therapy,-disease,-and-geography---growth,-trends,-and-forecast-%282018---2023%29/pr-17149

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.